Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice

Department of Pharmacology, Tulane University, 1430 Tulane Ave, New Orleans LA 70112, USA.
Arteriosclerosis Thrombosis and Vascular Biology (Impact Factor: 5.53). 06/2008; 28(8):1432-8. DOI: 10.1161/ATVBAHA.108.167205
Source: PubMed

ABSTRACT Type 2 diabetes is associated with increased advanced glycation end product (AGE) formation and vasculopathy. We hypothesized that AGEs contribute to resistance artery dysfunction.
Type 2 diabetic db(-)/db(-) (diabetic) and nondiabetic db(-)/db(+) (control) mice were treated with the AGE inhibitor (aminoguanidine: 50 mg/Kg/d) for 3 months. Isolated mesenteric resistance arteries (MRAs) were mounted in an arteriograph. Pressure-induced myogenic tone (MT) was increased in diabetic mice but was unaffected by aminoguanidine treatment. Phenylephrine-induced contraction and nitric oxide donor-induced endothelium-independent relaxation were similar in all groups. In diabetic mice, endothelium-dependent relaxation in response to shear-stress or acetylcholine was altered and was associated with reduced eNOS protein and mRNA expression. Aminoguanidine treatment improved endothelial function and restored eNOS expression. AGE formation and hypoxia markers (plasminogen activator inhibitor 1 and Bnip3) were increased in MRA from diabetic mice and normalized with Aminoguanidine. Primary cultured endothelial cells (ECs) isolated from resistance arteries subjected to high glucose for 48 hours showed decreased eNOS expression and phosphorylation in response to calcium ionophore. High glucose decreased antioxidant protein (MnSOD) and increased prooxidant proteins (gp91phox) expression leading to increased oxidative stress generation, as assessed by DHE staining and endothelial NADH/NADPH oxidase activity. The preincubation of ECs with aminoguanidine restored eNOS-phosphorylation and expression as well as the balance between pro- and antioxidant factors induced by high glucose.
We provide evidence of a link between AGEs, oxidative stress, and resistance artery EC dysfunction in type 2 diabetic mice. Thus, AGEs and oxidative stress may be a potential target for overcoming diabetic microvessels complications.

Download full-text


Available from: Romer Gonzalez-Villalobos, Aug 21, 2015
1 Follower
  • Source
    • "It is importat to note that Nox4 have been recently identified as a mitochondrial cytochrome c oxidase subunit IV as being an additional source of ROS in diabetes [55]. An elevation in Nox activity in hyperglycemia can be mediated by AGEs through their specific receptors (RAGEs) that increase Nox subunit gp91 expression [51] [56] [57]. Hyperglycemia can increase an expression of Nox, as it has been shown in endothelium and vascular SMCs [18] [37] [43] [47] [50] [54]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes mellitus (DM) is a complex syndrome which leads to multiple dysfunctions including vascular disorders. Hyperglycemia is considered to be a key factor responsible for the development of diabetic vascular complications and can mediate their adverse effects through multiple pathways. One of those mechanisms is the activation of protein kinase C (PKC). This important regulatory enzyme is involved in a signal transduction of several vascular functions including vascular smooth muscle contractility. Many studies have shown that hyperglycemia in DM results in oxidative stress. Overproduction of reactive oxygen species (ROS) by different oxidases and the mitochondrial electron transport chain (ETC), advanced glycation end products, polyol pathway flux, and hyperglicemia-induced rising in diacylglycerol (DAG) contribute to the activation of PKC. Activation of endothelial PKC in DM leads to endothelium-dependent vasodilator dysfunction. The main manifestations of this are inhibition of vasodilatation mediated by nitric oxide (NO), endothelium-derived hyperpolarizing factor (EDHF) and prostacyclin, and activation of vasoconstriction mediated by endothelin-1 (ET-1), prostaglandin E2 (PGE2) and thromboxane A2 (TXA2). Activated PKC in DM also increases vascular endothelial growth factor (VEGF) expression and activates NADPH oxidases leading to raised ROS production. On the other hand, PKC in DM is involved in enhancement of vascular contractility in an endothelium-independent manner by inactivation of K(+) channels and Ca(2+) sensitization of myofilaments in vascular smooth muscle cells. This shows that PKC is a potential therapeutic target for treating vascular diabetic complications.
    International journal of cardiology 04/2014; 174:230-242. DOI:10.1016/j.ijcard.2014.04.117 · 6.18 Impact Factor
  • Source
    • "There is evidence that glycation of protein depends on the oxidation of glucose since the product of glucose oxidation is attached to the protein to generate AGEs [40]. AGEs mediate increased NADPH subunit gp91 expression, NADH/NADPH oxidase activity, and decreased manganese super oxide dismutase (MnSOD) levels [41]. This finding indicates that AGEs play key pathophysiological roles in increasing oxidative stress in diabetes along with subsequent endothelial dysfunction through decreasing endothelial nitric oxide synthase (eNOS) phosphorylation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes mellitus (DM) is a chronic metabolic disorder characterized by inappropriate hyperglycemia due to lack of or resistance to insulin. Patients with DM are frequently afflicted with ischemic vascular disease or wound healing defect. It is well known that type 2 DM causes amplification of the atherosclerotic process, endothelial cell dysfunction, glycosylation of extracellular matrix proteins, and vascular denervation. These complications ultimately lead to impairment of neovascularization and diabetic wound healing. Therapeutic angiogenesis remains an attractive treatment modality for chronic ischemic disorders including PAD and/or diabetic wound healing. Many experimental studies have identified better approaches for diabetic cardiovascular complications, however, successful clinical translation has been limited possibly due to the narrow therapeutic targets of these agents or the lack of rigorous evaluation of pathology and therapeutic mechanisms in experimental models of disease. This paper discusses the current body of evidence identifying endothelial dysfunction and impaired angiogenesis during diabetes.
    International journal of vascular medicine 02/2012; 2012:918267. DOI:10.1155/2012/918267
  • Source
    • "Food and water were given ad libitum in a controlled environment (room temperature 21–22 • C, room humidity 50 ± 5%) until the rats were 37–42 weeks old. OLETF and LETO rats were randomly allocated to receive either 50 mg/kg/day [57] of aminoguanidine (AG; Wako Pure Chemical Co. Ltd., Osaka, Japan) in the 5% HCl drinking water for 10 weeks starting at 27–32 weeks old, or to receive the 5% HCl drinking water for a similar term. Thus, we studied four groups: AG-untreated LETO and OLETF groups and AG-treated LETO and OLETF groups. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Circulating levels of endothelin (ET)-1 are increased in the diabetic state, as is endogenous ET(A)-receptor-mediated vasoconstriction. However, the responsible mechanisms remain unknown. We hypothesized that ET-1-induced vasoconstriction is augmented in type 2 diabetes with hyperglycemia through an increment in advanced glycation end-products (AGEs). So, we investigated whether treatment with aminoguanidine (AG), an inhibitor of AGEs, would normalize the ET-1-induced contraction induced by ET-1 in strips of thoracic aortas isolated from OLETF rats at the chronic stage of diabetes. In such aortas (vs. those from age-matched genetic control LETO rats): (1) the ET-1-induced contraction was enhanced, (2) the levels of HIF1α/ECE1/plasma ET-1 and plasma CML-AGEs were increased, (3) the ET-1-stimulated ERK phosphorylation mediated by ET(A)-R was increased, (4) the expression level of Jab1-modified ET(A)-R protein was reduced, and (5) the expression level of O-GlcNAcylated ET(A)-R protein was increased. Aortas isolated from such OLETF rats that had been treated with AG (50mg/kg/day for 10 weeks) exhibited reduced ET-1-induced contraction, suppressed ET-1-stimulated ERK phosphorylation accompanied by down-regulation of ET(A)-R, and increased modification of ET(A)-R by Jab1. Such AG-treated rats exhibited normalized plasma ET-1 and CML-AGE levels, and their aortas exhibited decreased HIF1α/ECE1 expression. However, such AG treatment did not alter the elevated levels of plasma glucose or insulin, or systolic blood pressure seen in OLETF rats. These data from the OLETF model suggest that within the timescale studied here, AG normalizes ET-1-induced aortic contraction by suppressing ET(A)-R/ERK activities and/or by normalizing the imbalance between Jab1 and O-GlcNAc in type 2 diabetes.
    Peptides 11/2011; 33(1):109-19. DOI:10.1016/j.peptides.2011.11.018 · 2.61 Impact Factor
Show more